公开(公告)号：US20150322020A1

公开(公告)日：2015-11-12

申请号：US14762554

申请日：2014-01-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  Paul Michael Scola

IPC: C07D251/52 ,  A61K45/06 ,  C07D403/12 ,  A61K31/53

CPC classification number: C07D251/52 ,  A61K31/53 ,  A61K45/06 ,  C07D403/12

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract translation: 除了使用这些化合物的组合物和方法之外，还列举了式I化合物，包括其药学上可接受的盐。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：US20150232414A1

公开(公告)日：2015-08-20

申请号：US14704183

申请日：2015-05-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： YASUTSUGU UEDA ,  Timothy P. Connolly ,  John F. Kadow ,  Nicholas A. Meanwell ,  Tao Wang ,  Chung-Pin H. Chen ,  Kap-Sun Yeung ,  Zhongxing Zhang ,  David Kenneth Leahy ,  Shawn K. Pack ,  Nachimuthu Soundararajan ,  Pierre Sirard ,  Kathia Levesque ,  Dominique Thoraval

IPC: C07C215/10 ,  C07D471/04

CPC classification number: A61K31/675 ,  A61K31/497 ,  A61K31/519 ,  A61K45/06 ,  C07C215/10 ,  C07D471/04 ,  C07F9/062 ,  C07F9/5728 ,  C07F9/65515 ,  C07F9/65586 ,  C07F9/6561

Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

Abstract translation: 本发明提供前药化合物I，其药物组合物及其在治疗HIV感染中的用途。 其中：X为C或N，条件是当X为N时，R1不存在; W为C或N，条件是当W为N时，R2不存在; V是C; E是氢或其药学上可接受的盐; 并且Y选自本发明另外，本发明提供了可用于制备前药化合物I的中间体化合物II。其中：L和M独立地选自C 1 -C 6烷基，苯基，苄基，三烷基甲硅烷基， 2,2,2-三氯乙氧基和2-三甲基甲硅烷基乙氧基。

公开(公告)号：US20150105394A1

公开(公告)日：2015-04-16

申请号：US14384410

申请日：2013-03-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  John F. Kadow ,  Nicholas A. Meanwell ,  Lawrence G. Hamann

IPC: C07D471/04 ,  A61K45/06 ,  A61K31/519 ,  A61K31/501

CPC classification number: C07D471/04 ,  A61K31/501 ,  A61K31/519 ,  A61K45/06 ,  C07D519/00

Abstract: Compounds of Formula I are provided, including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: wherein Z is selected from the group consisting of: which are useful as HIV attachment inhibitors.

Abstract translation: 提供式I化合物，包括其药学上可接受的盐：其中A选自：其中Z选自：其可用作HIV附着抑制剂。

公开(公告)号：US20150087652A1

公开(公告)日：2015-03-26

申请号：US14493515

申请日：2014-09-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  Nicholas A. Meanwell ,  John F. Kadow ,  Zhiwei Yin ,  Qiufen May Xue ,  Alicia Regueiro-Ren ,  John D. Matiskella ,  Yasutsugu Ueda

IPC: A61K31/496 ,  A61K45/06

CPC classification number: C07D471/04 ,  A61K31/496 ,  A61K45/06 ,  C07D491/048

Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

Abstract translation: 本发明提供具有药物和生物影响性质的化合物，其药物组合物和使用方法。 特别地，本发明涉及氮杂吲哚乙酰基哌嗪衍生物。 这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药，抗感染剂，免疫调节剂或HIV进入抑制剂组合使用。 更具体地说，本发明涉及艾滋病毒和艾滋病的治疗。

公开(公告)号：US20140134130A1

公开(公告)日：2014-05-15

申请号：US14073984

申请日：2013-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhiwei Yin ,  Paul Michael Scola

IPC: C07D487/04 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/53

CPC classification number: C07D487/04 ,  A61K31/53 ,  A61K45/06 ,  A61K2300/00

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:

Abstract translation: 式I化合物，包括其药学上可接受的盐，以及含有这些化合物的组合物具有抗丙型肝炎病毒（HCV）的活性，并且可用于治疗感染HCV的患者：